WO2014161004A3 - Compositions et procédés pour l'administration de médicaments à la surface oculaire par des lentilles de contact - Google Patents

Compositions et procédés pour l'administration de médicaments à la surface oculaire par des lentilles de contact Download PDF

Info

Publication number
WO2014161004A3
WO2014161004A3 PCT/US2014/032412 US2014032412W WO2014161004A3 WO 2014161004 A3 WO2014161004 A3 WO 2014161004A3 US 2014032412 W US2014032412 W US 2014032412W WO 2014161004 A3 WO2014161004 A3 WO 2014161004A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
drugs
delivery
contact lenses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/032412
Other languages
English (en)
Other versions
WO2014161004A2 (fr
Inventor
John Andrew MACKAY
Wan Wang
Gordon W. Laurie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US14/781,226 priority Critical patent/US20180094137A1/en
Publication of WO2014161004A2 publication Critical patent/WO2014161004A2/fr
Publication of WO2014161004A3 publication Critical patent/WO2014161004A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00—Compositions of proteins; Compositions of derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
    • G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
    • G02B1/041—Lenses
    • G02B1/043—Contact lenses
    • G—PHYSICS
    • G02—OPTICS
    • G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00—Optical parts
    • G02C7/02—Lenses; Lens systems ; Methods of designing lenses
    • G02C7/04—Contact lenses for the eyes
    • G02C7/049—Contact lenses having special fitting or structural features achieved by special materials or material structures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Materials Engineering (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne de nouveaux procédés et de nouvelles compositions pour cibler des maladies oculaires. Un aspect concerne une lentille de contact comprenant un composant de peptide de type élastine (ELP) et facultativement un agent thérapeutique. L'invention concerne également des procédés de traitement de maladies oculaires comprenant l'administration d'une lentille de contact de l'invention à un sujet en ayant besoin.
PCT/US2014/032412 2013-03-29 2014-03-31 Compositions et procédés pour l'administration de médicaments à la surface oculaire par des lentilles de contact Ceased WO2014161004A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/781,226 US20180094137A1 (en) 2013-03-29 2014-03-31 Compositions and methods for the delivery of drugs to the ocular surface by contact lenses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361806558P 2013-03-29 2013-03-29
US61/806,558 2013-03-29

Publications (2)

Publication Number Publication Date
WO2014161004A2 WO2014161004A2 (fr) 2014-10-02
WO2014161004A3 true WO2014161004A3 (fr) 2014-11-13

Family

ID=51625695

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/032412 Ceased WO2014161004A2 (fr) 2013-03-29 2014-03-31 Compositions et procédés pour l'administration de médicaments à la surface oculaire par des lentilles de contact

Country Status (2)

Country Link
US (1) US20180094137A1 (fr)
WO (1) WO2014161004A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130210747A1 (en) 2012-02-13 2013-08-15 University Of Southern California Methods and Therapeutics Comprising Ligand-Targeted ELPs
EP3229845B1 (fr) 2014-12-10 2020-05-27 University of Southern California Génération de transporteurs d'oxygène à base d'hémoglobine à l'aide de polypeptides de type élastine
MX394623B (es) 2016-02-04 2025-03-24 Ads Therapeutics Llc Tecnología de sinergismo anticuerpo-fármaco para el tratamiento de enfermedades.
US11464867B2 (en) 2018-02-13 2022-10-11 University Of Southern California Multimeric elastin-like polypeptides
IT201800005599A1 (it) * 2018-05-22 2019-11-22 Lente a contatto morbida
EP3594229A1 (fr) * 2018-07-11 2020-01-15 Universidad De Valladolid Biopolymère recombinant pour la détection de protéases
CA3175124A1 (fr) * 2020-03-11 2021-09-16 Brien Holden Vision Institute Limited Lentilles ophtalmiques et procedes de correction, de ralentissement, de reduction et/ou de controle de progression de la myopie en association avec l'utilisation d'atropine ou de composes apparentes
CN115960260B (zh) * 2022-09-30 2026-06-19 郑州伊美诺生物技术有限公司 一种重组抗原复合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013016578A2 (fr) * 2011-07-26 2013-01-31 University Of Southern California Libération contrôlée de produits biopharmaceutiques oculaires au moyen de polymères protéiques biosensibles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013016578A2 (fr) * 2011-07-26 2013-01-31 University Of Southern California Libération contrôlée de produits biopharmaceutiques oculaires au moyen de polymères protéiques biosensibles

Also Published As

Publication number Publication date
WO2014161004A2 (fr) 2014-10-02
US20180094137A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
HK1204988A1 (en) Methods and compositions for preventing or treating ophthalmic conditions
WO2014145159A3 (fr) Anticorps à charge génétiquement modifiée ou compositions de protéines de ciblage à pénétration améliorée et méthodes d'utilisation
NZ704247A (en) Compositions and treatment for eye diseases and disorders
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
CL2015002485A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares
EP2663281A1 (fr) Administration à la cornée d'agents de réticulation par ionophorèse pour le traitement de kératocône et compositions ophtalmologiques associées
MX361858B (es) Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares.
EA201590622A1 (ru) Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
WO2013034982A3 (fr) Peptides immunomodulateurs utilisables en vue du traitement de maladies neurodégénératives évolutives
IN2015DN00376A (fr)
HK1198811A1 (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent
WO2014160281A3 (fr) Procédé pour améliorer l'administration de composés thérapeutiques à l'œil
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
EA201501054A1 (ru) Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы
WO2013171764A3 (fr) Préparations ophtalmologiques
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
WO2014107730A3 (fr) Utilisation de conjugués d'acides gras et de niacine en vue du traitement de maladies
WO2013189606A3 (fr) Thérapie intermittente pour le traitement de la perte de la vision chez des êtres humains ayant un glaucome et d'autres maladies dégénératives de l'œil
EP3164412A4 (fr) Composition pharmaceutique comprenant un agent thérapeutique à base d'une protéine ou d'une sous-unité d'hémoglobine recombinée pour traitement ciblé du cancer
MA56220A (fr) Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil
UY36408A (es) Derivados de pirido benzodiazepina sustituidos y su utilización
IN2014CN00510A (fr)
GB2558494B (en) Protein nanostructure based drug delivery system for the delivery of therapeutic agents to the anterior segment of the eye
PH12016501347A1 (en) Filters for infusion sets
HK1219654A1 (zh) 用於治疗眼科疾病和病症的方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14774654

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14774654

Country of ref document: EP

Kind code of ref document: A2